Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04678921 | Study of TJ210001 Administered in Subjects With Relapsed or Refractory Advanced Solid Tumors | PHASE1 | COMPLETED | 16 | — | — | Dec 17, 2020 | Nov 21, 2022 | Dec 12, 2022 | 4 | United States |
The CTCAE criteria will be used to assess adverse events on this trial.
Based on DLT Definitions
| Arm | Type | Description |
|---|---|---|
| Dose Level 1 | EXPERIMENTAL | 1mg/kg Q1W |
| Dose Level 2 | EXPERIMENTAL | 3 mg/kg Q1W |
| Dose Level 3 | EXPERIMENTAL | 10mg/kg Q1W |
| Dose Level 4 | EXPERIMENTAL | 15 mg/kg Q1W |
| Name | Type | Description |
|---|---|---|
| TJ210001 | DRUG | human anti-C5aR monoclonal antibody |
Inclusion Criteria: 1. Males or females, of any race, age ≥ 18 years; 2. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1; 3. Willingness and ability to consent for self to participate in study and the ability to comply with scheduled visits, treatment plan, laboratory tests, and ot...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab, V503, GARDASIL |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| AstraZeneca PLC | AZN | 1 | — | Trastuzumab deruxtecan |